Key Highlights

  • Sales were USD 67.97 million against a USD 67.39 million estimate, and EPS was USD 0.65 against USD 0.69.
  • The October B. Braun asset purchase cost USD 19.2 million; those products recorded USD 9.4 million of 2025 sales.
  • Grafts rose 20% and shunts rose 14%, while Artegraft sales increased 18% and EMEA sales rose 18%.
  • 2026 guidance is sales of USD 274.8 million to USD 276.8 million and EPS of USD 2.77 to USD 2.82.

LeMaitre Vascular, Inc. (NASDAQ:LMAT) paired its third quarter report with an October Acquisition of certain vascular Assets from B. Braun for USD 19.2 million. The products, which include polyester and silver-coated grafts, valve cutters and vein strippers, recorded sales of USD 9.4 million in 2025, all outside North America. Third quarter sales were USD 67.97 million against an estimate of USD 67.39 million, and EPS was USD 0.65 against an estimate of USD 0.69.

How the Deal Fits the Quarter

The purchase closed after the quarter ended, so it is not part of the reported results. Management said the sales are to transition into its own channel over the next 18 to 24 months as B. Braun customer contracts conclude or transfer. During that period the company receives a portion of the profits on B. Braun-originated sales. Guidance includes approximately USD 150,000 of fourth quarter B. Braun product sales and a break-even Operating Income impact.

The chairman and chief executive, George LeMaitre, said the acquired products would strengthen the core vascular portfolio and lean on the company's 31-country sales force. He also pointed to Artegraft's international launch and RestoreFlow Allografts growth as Biologics drivers.

Results Around the Event

Sales rose 11% from USD 61.05 million, or 12% on an organic basis, made up of 7% from price and 5% from units. Grafts rose 20%, shunts rose 14% and Artegraft rose 18%. By region, EMEA sales increased 18%, the Americas 9% and APAC 5%.

Gross profit was USD 48.71 million and gross Margin was 71.7%, down 360 basis points, or up 90 basis points against the prior-year figure adjusted for a one-time Employee Retention Tax Credit benefit. Management tied the adjusted improvement to higher average selling prices and operational efficiencies. Operating expenses were USD 31.01 million, up 21% or 18% on an adjusted basis, which management linked to belt-tightening in the third quarter of 2025.

Operating income was USD 17.70 million, against USD 20.31 million, for a 26% operating margin. Net Income was USD 15.02 million, against USD 17.36 million, and diluted EPS of USD 0.65 compares with USD 0.75.

Cash, Capital Returns and Guidance

Cash was USD 390 million at September 30, up USD 13.5 million from the previous quarter. Convertible senior notes, net, were USD 169.32 million, and Operating Cash Flow for the nine months was USD 53.05 million against USD 58.09 million.

Fourth quarter guidance is sales of USD 69.9 million to USD 71.9 million, operating income of USD 18.8 million to USD 20.2 million and EPS of USD 0.70 to USD 0.75, at a gross margin of 72.1%. Full year guidance is sales of USD 274.8 million to USD 276.8 million, operating income of USD 74.6 million to USD 76.1 million and EPS of USD 2.77 to USD 2.82.

A quarterly Dividend of USD 0.25 per share was approved on October 27, 2026. A repurchase authorization of up to USD 100.0 million remains in place through February 18, 2027, unless extended by the Board.

Reference Points for Investors

Sales of USD 67.97 million sit alongside gross margin of 71.7%, operating income of USD 17.70 million and EPS of USD 0.65. Cash of USD 390 million compares with convertible notes of USD 169.32 million.

Management named dated items: the USD 0.25 dividend payable December 3, 2026 to holders of record on November 19, a repurchase program that concludes February 18, 2027, and an 18 to 24 month transition of B. Braun sales. Its fourth quarter guidance cites midpoints of USD 70.9 million of sales and USD 0.73 of EPS.